Table 1.
Demographic, clinical manifestations, and medications of study groups
| Group 1 (botulinum), N: 16 (22 fingers) | Group 2 (prostaglandin analogs), N: 10 (21 fingers) | |
|---|---|---|
| Demographic characteristics | ||
| Women, n (%) | 11 (68.7) | 9 (90) |
| Men, n (%) | 5 (31.2) | 1 (10) |
| Age, median (range) | 39.5 (25–60) | 51.5 (28–63) |
| Duration of disease from Raynaud’s (years), median (range) | 8 (1–25) | 11 (3–35) |
| Clinical features | ||
| Diffuse SSc, n (%) | 5 (31.2) | 1 (10) |
| Limited SSc, n (%) | 11 (68.7) | 9 (90) |
| Raynaud’s, n (%) | 16 (100) | 10 (100) |
| Digital ulcers, n (%) | 16 (100) | 10 (100) |
| Cardiac involvement, n (%) | 0 (0) | 0 (0) |
| Gastrointestinal involvement, n (%) | 14 (87.5) | 9 (90) |
| Interstitial lung disease, n (%) | 11 (68.7) | 6 (60) |
| Pulmonary hypertension (PAP > 35 mmHg), n (%) | 0 (0) | 0 (0) |
| Modified Rodnan skin score, median (range) | 14 (4–28) | 14.5 (4–23) |
| Finger to palm limitation, n (%) | 5 (31.2) | 5 (50) |
| Medications | ||
| Prednisolone, n (%) | 14 (87.5) | 5 (50) |
| Rituximab, n (%) | 4 (25) | 1 (10) |
| Aspirin, n (%) | 14 (87.5) | 5 (50) |
| Methotrexate, n (%) | 2 (12.5) | 1 (10) |
| Mycophenolate mofetil, n (%) | 4 (25) | 4 (40) |
| Pentoxifylline, n (%) | 5 (31.2) | 2 (20) |
| Calcium channel blockers, n (%) | 16 (100) | 10 (100) |
| Sildenafil or tadalafil, n (%) | 7 (43.7) | 3 (30) |
Data are n (%) unless otherwise indicated. SSc, systemic sclerosis; PAP, pulmonary artery hypertension